Clinical Trials Directory

Trials / Unknown

UnknownNCT01005173

Acetaminophen Biomarkers

Identification of New Mechanistic Biomarkers of Adverse Response to Acetaminophen

Status
Unknown
Phase
Study type
Observational
Enrollment
253 (estimated)
Sponsor
Arkansas Children's Hospital Research Institute · Academic / Other
Sex
All
Age
1 Year – 18 Years
Healthy volunteers
Accepted

Summary

This study is a non-intervention, multicenter study to address biomarkers of acetaminophen toxicity in children. Specifically, the study will examine acetaminophen (APAP) protein adducts and markers of liver injury in the blood samples of hospitalized children and adolescents who are receiving standard doses of acetaminophen, and children and adolescents who are status post acetaminophen overdose. Ultimately, the data generated from this study will be used to establish second generation biomarkers of acetaminophen toxicity, based on specific adduct proteins, which can be used in future risk assessment studies of children receiving acetaminophen.

Conditions

Timeline

Start date
2009-08-01
Primary completion
2018-06-01
First posted
2009-10-30
Last updated
2017-11-24

Locations

8 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01005173. Inclusion in this directory is not an endorsement.

Acetaminophen Biomarkers (NCT01005173) · Clinical Trials Directory